Biologics in asthma--the next step toward personalized treatment.

[1]  K. Rothman,et al.  Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. , 2014, The Journal of allergy and clinical immunology.

[2]  L. Boulet,et al.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. , 2014, The New England journal of medicine.

[3]  S. Walker,et al.  Omalizumab for asthma in adults and children. , 2014, The Cochrane database of systematic reviews.

[4]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[5]  Ruksha Bhadresha.  Dupilumab in persistent asthma with elevated eosinophil levels , 2013, Thorax.

[6]  K. Bracke,et al.  Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma , 2013, Nature Medicine.

[7]  S. Spector,et al.  High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. , 2013, The Journal of allergy and clinical immunology.

[8]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[9]  D. Broide,et al.  Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. , 2013, The Journal of allergy and clinical immunology.

[10]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[11]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[12]  M. Humbert,et al.  A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. , 2013, Chest.

[13]  S. Walker,et al.  Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years , 2012, PharmacoEconomics.

[14]  G. Joos,et al.  Targeting interleukin-4 in asthma: lost in translation? , 2012, American journal of respiratory cell and molecular biology.

[15]  A. Vatrella,et al.  The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.

[16]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[17]  W. Busse,et al.  Omalizumab and the risk of malignancy: results from a pooled analysis. , 2012, The Journal of allergy and clinical immunology.

[18]  James B. Young,et al.  Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. , 2012, The Journal of allergy and clinical immunology.

[19]  Aasia I. Ghazi,et al.  Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma , 2012, Expert opinion on biological therapy.

[20]  A. McKenzie,et al.  Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. , 2012, The Journal of allergy and clinical immunology.

[21]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[22]  H. Ortega,et al.  An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. , 2011, Gastroenterology.

[23]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[24]  S. Spector,et al.  A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. , 2011, The Journal of allergy and clinical immunology.

[25]  F. Simons,et al.  American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. , 2011, The Journal of allergy and clinical immunology.

[26]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[27]  S. Walker,et al.  Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. , 2011, Health technology assessment.

[28]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[29]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[30]  S. Nakae,et al.  IL-33 and Airway Inflammation , 2011, Allergy, asthma & immunology research.

[31]  M. Humbert,et al.  Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma. , 2010, Respiratory medicine.

[32]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[33]  Sally E Wenzel,et al.  A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.

[34]  W. Busse,et al.  A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. , 2010, The Journal of allergy and clinical immunology.

[35]  J. Drazen,et al.  Choosing asthma step-up care. , 2010, The New England journal of medicine.

[36]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[37]  P. Barnes,et al.  The cytokine network in asthma and chronic obstructive pulmonary disease. , 2008, The Journal of clinical investigation.

[38]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[39]  Ruslan Medzhitov,et al.  A mechanism for the initiation of allergen-induced T helper type 2 responses , 2008, Nature Immunology.

[40]  B. O'connor,et al.  Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. , 2005, Journal of immunology.

[41]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[42]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[43]  D. DeMeo,et al.  Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood. , 2007, The Journal of allergy and clinical immunology.

[44]  T. Raum,et al.  A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. , 2007, Molecular immunology.

[45]  R. Polosa,et al.  Study of infliximab treatment in asthma. , 2007, American journal of respiratory and critical care medicine.

[46]  P. Barnes,et al.  The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-α in Asthma , 2006 .

[47]  Dave P. Miller,et al.  High Prevalence of Skin Test Positivity in Severe or Difficult-to-Treat Asthma , 2006, The Journal of asthma : official journal of the Association for the Care of Asthma.

[48]  P. Barnes,et al.  The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. , 2006, American journal of respiratory and critical care medicine.

[49]  A. Burks,et al.  Omalizumab , 2005, Clinical reviews in allergy and immunology.

[50]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[51]  M. Wills-Karp,et al.  Interleukin‐13 in asthma pathogenesis , 2004, Immunological reviews.

[52]  J. Steinke.  Anti-interleukin-4 therapy. , 2004, Immunology and allergy clinics of North America.

[53]  Stephen T Holgate,et al.  Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. , 2004, American journal of respiratory and critical care medicine.

[54]  J. Bousquet,et al.  Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. , 2004, Chest.

[55]  T. Casale,et al.  Omalizumab treatment downregulates dendritic cell FcεRI expression , 2003 .

[56]  T. Casale,et al.  Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. , 2003, The Journal of allergy and clinical immunology.

[57]  T. Casale,et al.  Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. , 2003, The Journal of allergy and clinical immunology.

[58]  M. Brigham-Burke,et al.  Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti‐interleukin‐4 antibody with therapeutic potential in asthma , 2002, Clinical and experimental immunology.

[59]  K. Chung,et al.  Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. , 2001, American journal of respiratory and critical care medicine.

[60]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[61]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[62]  K. Leong,et al.  Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma. , 1999, The Journal of allergy and clinical immunology.

[63]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[64]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[65]  A. Togias,et al.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.

[66]  R. Strieter,et al.  TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. , 1995, Journal of immunology.

[67]  L. Presta,et al.  Inhibition of allergic reactions with antibodies to IgE. , 1995, International archives of allergy and immunology.